GRM5 and fragile X syndrome: Ongoing clinical trials using mGlu5 modulators in neurodegenerative diseases, including AD and PD, as well as other neurological conditions, such as FXS, will help elucidate the role of the mGlu5 in different disease mechanisms and its therapeutic potential in neurodegenerative disorders.